Alopexx   Report issue

For profit Phase 2
Founded: Concord MA United States (2011)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2013
NCT01874288
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Alopexx Oncology, LLC | Alopexx Pharmaceuticals, LLC | Alopexx Vaccine, LLC

Active Ingredients

Drugs in Phase 2 Trials (3)

av0328 (1 trial)

di-leu16-il2 (2 trials)

f598 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gonorrhea (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3